产品
编 号：F752079
分子式：C13H11FN2O5S
分子量：326.3
分子式：C13H11FN2O5S
分子量：326.3
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2407610-46-0
产品详情
生物活性：
Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC50s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively.
体内研究：
Tegeprotafib (Compound 124; 300 mg/kg; oral; BID for 21 days) 在小鼠中具有抗肿瘤活性。Animal Model:Female C57B1/6 mice, MC-38 tumor model
Dosage:300 mg/kg/dose
Administration:Oral, twice a day (BID) at 7am and 5pm for 21 days
Result:Within 7-10 days of treatment, apparent tumor stasis and shrinkage was observed. 50% of mice achieved complete cures, and an overall TGIMEX was 75%. The frequency of functional, granzyme B (GzB) producing cells within the cytotoxic CD8+ T population in the spleen was 2.9-fold increased over vehicle control treated animals. Increased IP10 levels in plasma.
体外研究：
Tegeprotafib (Compound 124; 5 days) 抑制 IFNγ (0.5 ng/mL) 诱导的 B16F10 细胞生长，33 μM 的生长抑制率为 60-90%。
Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC50s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively.
体内研究：
Tegeprotafib (Compound 124; 300 mg/kg; oral; BID for 21 days) 在小鼠中具有抗肿瘤活性。Animal Model:Female C57B1/6 mice, MC-38 tumor model
Dosage:300 mg/kg/dose
Administration:Oral, twice a day (BID) at 7am and 5pm for 21 days
Result:Within 7-10 days of treatment, apparent tumor stasis and shrinkage was observed. 50% of mice achieved complete cures, and an overall TGIMEX was 75%. The frequency of functional, granzyme B (GzB) producing cells within the cytotoxic CD8+ T population in the spleen was 2.9-fold increased over vehicle control treated animals. Increased IP10 levels in plasma.
体外研究：
Tegeprotafib (Compound 124; 5 days) 抑制 IFNγ (0.5 ng/mL) 诱导的 B16F10 细胞生长，33 μM 的生长抑制率为 60-90%。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备